Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics ...
Researchers are redesigning lipid nanoparticles to do more than shuttle mRNA into cells, with preclinical studies suggesting ...
Researchers identify a gene expression program in the living human brain that tracks with real-time neurotransmission, bridging the gap between genetics and electrical brain activity.
Infectious keratitis remains a leading cause of corneal blindness and visual impairment worldwide, with bacterial, fungal, amoebic and viral pathogens presenting major diagnostic and therapeutic ...
Learn about comparative gene expression studies in Alzheimer's disease and other conditions in Mayo Clinic's Precision Medicine in Neurodegeneration Lab.